 distribut unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
beat rais plu record book quarter show
manag execut strategi give us increas
confid inflect point rais pt
strong beat rais showcas execut plan iqvia top ms/con
estim revenu ebitda ep rais guidanc reflect
stronger organ growth rais higher expect pass
revenu tuck acquisit manag rais
top-line guidanc million bp midpoint billion
billion billion previous versu con
billion compani also increas ebitda guidanc million
vs prior million consensu million ep
vs prior consensu driven organ
growth pass through tuck in minim impact profit
nextgen orchestr custom engag oce continu gain
traction nextgen award million grew sequenti bring
total award billion sinc product launch billion
end billion win rate iqvia goe
market nextgen compar legaci quintil showcas
differenti offer compani also see momentum oce
use artifici intellig machin learn aid pharma
manufactur commerci plan second technolog enabl
product launch ims/quintil merger aim displac current
commerci share leader syneo launch oce decemb
compani engag includ top pharma compani
implement product global top pharma client roll
oce top pharma market global specialti mid-size pharma
compani deploy oce countri
still target growth inflect point result increas confid
potenti upsid manag highlight execut give
confid plan acceler growth typic
award contract convert revenu first year trial
mean strong book start meaning impact top-line
growth end consist guidanc time period
market share gain pick drive organ growth toward long
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
term goal high singl digit
updat model estim rais price target
model revenu million vs prior estim
million rais ep estim
vs prior estim also chang bull case
valu bear case valu
dcf deriv termin growth wacc
revenu growth come ahead guid top-line compound-annual-growth-rate
ebitda growth synergi ramp translat
ebitda compound-annual-growth-rate
iqvia execut plan top-line compound-annual-growth-rate ebitda
growth synergi ramp translat ebitda
compound-annual-growth-rate in-line manag guidanc
growth miss mark top-line compound-annual-growth-rate ebitda
growth translat ebitda compound-annual-growth-rate
quintiles/im combin cro
bellweth combin clinic expertis
inform analyt cro busi
posit combin compani
leader futur
cut revenu synergi
provid earn boost next year
compani posit servic
pharma manufactur longer term drug
strateg partnership larg pharma
quarterli result focu backlog
risk achiev price
strateg deal lead price pressur
im synergi fail materi
client servic disrupt result
im merger integr
inform opinion research prepar co llc and/or and/or morgan
stanley mexico de bolsa de and/or canada limit use disclosur section includ morgan
stanley co llc mexico de bolsa de canada limit affili
necessari
import disclosur stock price chart equiti rate histori regard compani subject report pleas see morgan
stanley research disclosur websit www morganstanley com/researchdisclosur contact invest repres
research broadway attent research manag new york ny usa
valuat methodolog risk associ recommend rate price target referenc research report pleas contact client
support follow us/canada hong kong latin america london
singapor sydney tokyo altern may contact invest repres morgan
stanley research broadway attent research manag new york ny usa
follow analyst herebi certifi view compani secur discuss report accur express
receiv receiv direct indirect compens exchang express specif recommend view report ricki
unless otherwis state individu list cover page report research analyst
morgan stanley research publish accord conflict manag polici avail
import us regulatori disclosur subject compani
june benefici own class common equiti secur follow compani cover morgan
within last month manag co-manag public offer offer secur inc express script inc
within last month receiv compens invest bank servic amerisourcebergen corp inc charl
next month expect receiv intend seek compens invest bank servic allscript healthcar
diplomat pharmaci inc express script inc laboratori corp america hold mckesson corpor
within last month receiv compens product servic invest bank servic
within last month provid provid invest bank servic invest bank client relationship
follow compani inc amerisourcebergen corp athenahealth inc inc
corp america hold mckesson corpor medidata solut inc qualiti system inc
within last month either provid provid non-invest bank securities-rel servic and/or past
enter agreement provid servic client relationship follow compani amerisourcebergen corp
employe director consult director health corp person research analyst member research
 co llc make market secur amerisourcebergen corp athenahealth inc cardin
laboratori corp america hold mckesson corpor medidata solut inc qualiti system inc
equiti research analyst strategist princip respons prepar research receiv compens base upon
variou factor includ qualiti research investor client feedback stock pick competit factor firm revenu overal invest bank
revenu equiti research analyst strategist compens link invest bank capit market transact perform morgan
stanley profit revenu particular trade desk
affili busi relat companies/instru cover research includ market make provid
liquid fund manag commerci bank extens credit invest servic invest bank sell buy
custom securities/instru compani cover research princip basi may posit debt
compani instrument discuss report trade may trade princip debt secur relat deriv
subject debt research report
certain disclosur list also complianc applic regul non-u jurisdict
